Dr. Foldvari's research focuses on the development of intelligent delivery systems and biomolecular devices with the goal of developing new, non-invasive technologies to deliver and target therapeutic agents into the body and to diseased tissues, as well as investigating the fundamental properties of these delivery technologies and the cells they target.
Major Department Affiliation: School of Pharmacy
Dr. Foldvari also holds cross-appointments at the Department of Chemistry and Chemical Engineering at the University of Waterloo.
BSc Pharmacy (Semmelweis Medical University)
DPharmSci (Semmelweis Medical University)
PhD Pharmaceutical Sciences (Dalhousie University)
PHARM 126 Pharmaceutical Calculations
PHARM 604 Gene Therapy
Scholarly and Professional Activities
Editor of the Hot Topic Issue on “Nanomedicine - the application of nanotechnology to develop better treatments for patients" for Current Drug Delivery (2011)
Associate Editor, Nanomedicine: Nanotechnology, Biology, and Medicine (2006 – Present)
Dr. Foldvari continues to conduct collaborative research with her colleagues in the Western College of Veterinary Medicine and College of Pharmacy and Nutrition at the University of Saskatchewan in the areas of gene therapy and vaccine development. In other areas of non-invasive technologies to deliver therapeutic DNA and proteins into the body and to specifically target these therapeutics to diseased tissues she has collaborations at the Massachusetts Institute of Technology, Stanford University, Semmelweis University, University of Colorado, University College London and University of Queensland. She also collaborates with colleagues and research scientists at the National Synchrotron Light Source at Brookhaven National Laboratory in New York and the Canadian Light Source.
Drug & Vaccine Delivery Systems and Nanomedicine
For more information see Dr. Foldvari’s Research Group
- Elsabahy M, Foldvari M. Needle-free gene delivery through the skin: An overview of recent strategies. Curr Pharm Des. 2013.
- King M, Kumar P, Michel D, Batta R, Foldvari M. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application. European Journal of Pharmaceutics and Biopharmaceutics. 2013.
- Manfredi TG, Monteiro MA, Lamont LS, Singh MF, Foldvari M, White S, Cosmas AC, Urso ML. Postmenopausal effects of resistance training on muscle damage and mitochondria. J Strength Cond Res. 2013;27(2):556-561.
- Alqawlaq S, Huzil JT, Ivanova MV, Foldvari M. Challenges in neuroprotective nanomedicine development: Progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond). 2012;7(7):1067-1083.
- Badea I, Virtanen C, Verrall RE, Rosenberg A, Foldvari M. Effect of topical interferon-gamma gene therapy using gemini nanoparticles on pathophysiological markers of cutaneous scleroderma in tsk/+ mice. Gene Ther. 2012;19(10):978-987.
- Dong C, Alqawlaq S, Huzil T, Ivanova M, Elsabahy M, Santos AP, Foldvari M. Physical and transfection properties of non-viral gemini surfactant-phospholipid nanoparticles. Molecular Therapy. 2012;20:S159-S159.
- Donkuru M, Wettig SD, Verrall RE, Badea I, Foldvari M. Designing pH-sensitive gemini nanoparticles for non-viral gene delivery into keratinocytes. Journal of Materials Chemistry. 2012;22(13):6232-6244.
- Foldvari M. HPV infections: Can they be eradicated using nanotechnology? Nanomedicine. 2012;8(2):131-135.
- Foldvari M, Kumar P. Recent progress in the application of nanotechnology for prevention and treatment of human papillomavirus infection. Ther Deliv. 2012;3(8):1005-1017.
- Ivanova MV, Lamprecht C, Loureiro MJ, Huzil JT, Foldvari M. Pharmaceutical characterization of solid and dispersed carbon nanotubes as nanoexcipients. Int J Nanomedicine. 2012;7:403-415.